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ORIGINAL ARTICLE
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adolescent cohort in Myanmar
Nang Thu Thu Kyaw a, Ajay M. V. Kumarb,c, Myo Minn Oo a, Htun Nyunt Ood, Khine Wut Yee Kyaw a,
Soe Thiha a, Thet Ko Aung a, Than Wind, Yin Yin Mona and Anthony D. Harriesc,e
aThe Union Office in Myanmar, International Union Against Tuberculosis and Lung Disease, Mandalay, Myanmar; bThe Union South-East
Asia Regional Office, International Union Against Tuberculosis and Lung Disease, New Delhi, India; cResearch Department, International
Union Against Tuberculosis and Lung Disease, Paris, France; dDepartment of Public Health, National HIV/AIDS Program, Nay Pyi Taw,
Myanmar; eDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
ABSTRACT
Background: Myanmar has a high burden of Human Immunodeficiency Virus (HIV) and
second-line antiretroviral treatment (ART) has been available since 2008 in the public health
sector. However, there have been no published data about the outcomes of such patients
until now.
Objective: To assess the treatment and programmatic outcomes and factors associated with
unfavorable outcomes (treatment failure, death and loss to follow-up from care) among
people living with HIV (aged ≥ 10 years) receiving protease inhibitor-based second-line ART
under the Integrated HIV Care Program in Myanmar between October 2008 and June 2015.
Design: Retrospective cohort study using routinely collected program data.
Results: Of 824 adults and adolescents on second-line ART, 52 patients received viral load
testing and 19 patients were diagnosed with virological failure. However, their treatment was
not modified. At the end of a total follow-up duration of 7 years, 88 (11%) patients died, 35
(4%) were lost to follow-up, 21 (2%) were transferred out to other health facilities and 680
(83%) were still under care. The incidence rate of unfavorable outcomes was 7.9 patients per
100 person years follow-up. Patients with a history of injecting drug use, with a history of lost
to follow-up, with a higher baseline viral load and who had received didanosine and abacavir
had a higher risk of unfavorable outcomes. Patients with higher baseline C4 counts, those
having taken first-line ART at a private clinic, receiving ART at decentralized sites and taking
zidovudine and lamivudine had a lower risk of unfavorable outcomes.
Conclusions: Long-term outcomes of patients on second-line ART were relatively good in this
cohort. Virological failure was relatively low, possibly because of lack of viral load testing. No
patient who failed on second-line ART was switched to third-line treatment. The National HIV/
AIDS Program should consider making routine viral load monitoring and third-line ART drugs
available after a careful cost–benefit analysis.
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Background
Globally, the number of HIV-positive patients
accessing antiretroviral therapy (ART) has
doubled since 2010 and 17 million people were
on ART at the end of 2015 [1]. Mortality has
reduced and the survival among HIV-positive
patients has increased. Along with this benefit to
people living with HIV. (PLHIV), the need to
switch to second-line ART is also increasing
because there are more patients who are spending
longer periods of time on ART and failing on
first-line ART. With more treatment experience
on second-line ART, the numbers of patients fail-
ing this treatment and requiring third-line ART
are increasing.
Different rates of second-line ART treatment fail-
ure have been reported. Studies from Asia reported
that after two years on second-line ART, failure rates
ranged between 8% and 41% [2–4] and studies from
Africa reported that the rate was between 13% and
40% [3,5]. These studies have also described the dif-
ferent factors associated with second-line ART failure
such as duration on first-line ART, late detection of
first-line ART failure, current and prior ART regi-
mens, age, body mass index and patient adherence on
ART. Mortality rate was reported to be 13% at 5-year
follow-up of a second-line ART cohort in Vietnam
and 20% at 5-year follow-up in India [2,4]. High
mortality in patients who are on second-line ART
regimens and the challenges of managing this cohort
of patients in terms of adherence to ART drugs,
inadequate access to viral load monitoring and HIV
genotype testing, and cost of access to third-line ART
CONTACT Nang Thu Thu Kyaw nangthu82@gmail.com No.36, 27th Street, Bet: 72nd & 73rd Street, Mandalay, Myanmar
GLOBAL HEALTH ACTION, 2017
VOL. 10, 1290916
https://doi.org/10.1080/16549716.2017.1290916
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nl
oa
de
d 
by
 [L
on
do
n S
ch
oo
l o
f H
yg
ien
e &
 T
ro
p M
ed
ici
ne
] a
t 0
6:5
5 1
0 A
ug
us
t 2
01
7 
are of concern for programs treating PLHIV in
resource-limited countries [6–8].
Myanmar is one of the high-HIV-burden countries in
the South East Asia region with limited availability of
HIV viral load testing andHIV drug resistance testing for
monitoring patients who are on first-line as well as on
second-line ART [9]. Currently, more than 100,000
patients (54% of all PLHIV) are receiving ART in
Myanmar [9]. Although second-line ART has been avail-
able in the country since 2008, there are no published
data on the number of patients on second-line ART, the
characteristics of the cohort and their outcomes. With
the limited availability of second-line ART. drug options
and non-availability of third-line ART in the public
health sector in Myanmar, it is important to understand
the cohort of patients on second-line ART, their out-
comes and factors associated with unfavorable outcomes
on second-line treatment.
The Integrated HIV Care (IHC) Program has
been implementing activities within the public
sector via The Union Office in Myanmar, in col-
laboration with the National AIDS Program (NAP)
and National TB Control Program (NTP) since
2005. The program has been providing treatment
and chronic care for HIV-infected individuals in
different parts of Myanmar, including second-line
ART which has been available since 2008. This
study reports on the treatment and programmatic
outcomes of patients on second-line ART and the
factors associated with unfavorable outcomes
(treatment failure, death and loss to follow-up
from care) among PLHIV who were on second-
line ART after first-line ART failure in the IHC
Program in Myanmar between October 2008 and
June 2015.
Methods
Study design
This was a retrospective study of routinely col-
lected program data.
Study setting
Myanmar is one of the high-HIV-burden countries
with limited resources. The country is located in
Southeast Asia and administratively divided into
15 regions. The Union’s IHC Program works with
the NAP in the treatment and care of PLHIV at 33
sites in Mandalay, Sagaing, Magway, Shan and
Yangon regions. It has been providing HIV care
to about 30,000 patients since 2005, and about
23,000 patients are currently on ART under this
program. The HIV management and ART provi-
sion at IHC sites follow the NAP guidelines [10]
and all services including ART drugs and
laboratory investigations are provided free of
charge. A protease inhibitor-based second-line
ART has been available in the program since
2008. Currently, the national program recom-
mends second-line ART comprised of zidovudine
(ZDV) or tenofovir (TDF), lamivudine (3TC), and
ritonavir-boosted lopinavir (LPV/r) for adults and
adolescents. Before 2013, stavudine (D4T) and
didanosine (ddI) were used instead of ZDV, TDF
or abacavir (ABC).
Patients on the second-line ART regimens are
monitored clinically and immunologically. The pro-
gram follows the N.A.P guidelines for diagnosing
clinical, immunological and virological failure which
are based on World Health Organization (WHO)
guidelines [10,11]. Clinical failure is diagnosed by
the clinician if a patient develops a new or recurrent
WHO clinical stage III or IV condition after having
been on ART for 6 months or longer. Immunological
failure is diagnosed if the CD4 cell count falls to the
baseline or below, or stays persistently below 100
cells/µl after 6 months on ART. Routine HIV viral
load monitoring has not been available yet in this
setting. The program follows a system of targeted
viral load testing by which HIV viral load testing is
done when the patient is suspected to have clinical
and/or immunological failure. Virological failure is
diagnosed if a patient’s viral load is greater than
5000 copies/ml (before March 2015) or greater than
1000 copies/ml (after March 2015).
Viral load testing is carried out using an automated
c1000 RealTime PCR system (Bio-Rad Sciences,
Hercules, California, USA and HIV Generic Charge
Virale, Biocentric, Bandol, France) at the Public Health
Laboratory or using Rotor-Gene Real-Time Analysis
(PG. Biotech HIV detection kit) at an outside laboratory
if the in-house viral load machine is not available. The
CD4-count is measured by cyflow cytometry (Pertec-
sysmex, Wakinohama-kaigandari, Japan). HIV genotyp-
ing and drug resistance testing are not accessible for
routine practice and not available in the country. The
third-line ARV drugs such as ritonavir-boosted daruna-
vir (DRV) and atazanavir (ATV), etravirine (ETR) and
raltegravir (RAL), which are recommended in the NAP
2014 guidelines [10], are not available in the program.
However, there are a few patients who are on third-line
ART as a result of their own out-of-pocket expenditure
for those drugs.
Study population
We included all adult (age > 19 years) and adolescent
(between 10 and 19 years of age) PLHIV who initiated
protease inhibitor-based second-line treatment due to
documented clinical, immunological and/or virological
failure on first-line ART under the IHC Program
between 1 October 2008 and 31 June 2015. We excluded
2 N. T. T. KYAW ET AL.
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patients who started second-line ART before being regis-
tered to the IHC Program or who were on protease
inhibitors but did not have documentation of first-line
ART failure.
Variables
The data variables for the study included age, gender,
occupation, literacy, current sites of provision of sec-
ond-line ART, ART regimens, date of starting first-
line and second-line ART, clinical staging, CD4
counts and viral load result at the time of switching
to second-line ART, viral load (if available) on sec-
ond-line ART, date of CD4 and viral load testing, lost
to follow-up history, co-morbidities (Hepatitis B and
C), date of death, date of diagnosis of virological
failure, date of loss to follow-up, numbers of times
the first-line ART regimens were changed, duration
on treatment (first-line and second-line) and delayed
switching to second-line ART.
Duration on first-line ART was defined as the time
between the dates of starting first-line ART and start-
ing second-line ART. Duration on second-line ART
was defined as the time between the dates of start of
second-line ART and outcomes. Patients were con-
sidered to have had a ‘delayed switching to second-
line ART’ if the duration between date of virological
failure on first-line ART and date of starting second-
line ART was more than four months. A cutoff of
four months was used because as per national proto-
col, a first viral load result indicating failure criteria
was followed by intensive adherence counseling for
three months and a repeat viral load test was done
before making the switch.
The treatment outcome variables include virologi-
cally failed and not failed. The programmatic out-
come variables include regular follow-up (attending
clinic appointment regularly), death, lost to follow-
up, and transfer out to other facilities. As mentioned
earlier, we defined virological failure as a viral load
result greater than 5000 copies/ml before March 2015
and greater than 1000 copies/ml after March 2015.
We used the most recent date of a viral load result
that met the criteria for virological failure as the date
of diagnosis of virological failure. Death was recorded
if the patient’s family or the outreach workers
reported to the clinic that the patient had died.
Cause of death was not systematically recorded in
this setting. Lost to follow-up was defined as the
patient not attending the clinic within three months
after the scheduled appointment date.
We also categorized overall unfavorable outcome
which included patients who were categorized as
virological failure, dead or lost to follow-up.
Patients who were retained in care and transferred
out to other facilities without having virological
failure were categorized as having favorable out-
comes. For patients who died or were lost to fol-
low-up or transferred out, the date of the last
appointment before the event was considered as
the censor date. If a patient was lost to follow-up
from the program for more than three months and
then came back to the program, we considered that
he/she was ‘lost to follow-up at-least once’. If a
patient was lost to follow-up from care more than
once, the date of the most recent lost to follow-up
date was used as the censor date. Patients who were
on regular follow-up care without any other event
were categorized as having favorable outcomes and
31 December 2015 was considered as the censor
date.
Sources and collection of data
The data were all stored at the electronic patient
database which is regularly maintained and updated.
Data required for this study were extracted to a
Microsoft Excel file after removing patients’ identi-
fiers between February 2016 and April 2016.
Statistical analyses
The cumulative incidence (95% confidence interval
[CI]) of virological failure, death and loss to follow-
up was calculated using Kaplan–Meier methods. The
factors associated with unfavorable outcomes (virolo-
gical failure, dead and lost to follow-up) were ana-
lyzed using the Cox proportional hazard model.
Variables with a p-value < 0.2 in univariate analysis
were included in the multivariate model and adjusted
Hazard Ratios (HR) were calculated. Records with
missing covariates were excluded in the multivariate
model. Statistical analyses were performed using Stata
software [12].
Results
Between October 2008 and June 2015, 1538 adult and
adolescent patients were receiving ritonavir-boosted
lopinavir (LPV/r)-based second-line ART, out of
which 281 patients were already on LPV/r before
getting registered to IHC, 13 patients switched to
LPV/r due to toxicity and for 420 patients, no doc-
umentation on reason for switching was available.
Thus, only 824 patients who were switched from
first-line ART due to treatment failure were included
in this cohort analysis.
GLOBAL HEALTH ACTION 3
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Characteristics of the cohort
A total of 824 adult and adolescent patients with
mean age of 37 years (Standard deviation [S.D] 9
years) switched to second-line ART due to failure
on first-line ART. Baseline and follow-up character-
istics of this second-line cohort are shown in Table 1 .
About 65% were male and only 5% were from the
adolescent age group. Most were married, literate and
employed. Sixty-four percent of patients had a history
of taking ART at the private provider. Median and
interquartile range (IQR) duration on first-line ART
at IHC before switching to second-line ART was 27
(IQR 17–40) months. Date of first-line ART failure
was available for 761 patients with median duration
between failure on first-line ART and initiation of
second-line treatment being 2 (IQR 1–3) months.
Delayed switching occurred in 12% of them. Only
20% of the patients had a history of being lost to
follow-up under IHC care.
Baseline CD4 counts were available for 823 (99%)
patients and baseline HIV viral load tests were avail-
able for 560 (68%) patients. At the start of second-
line treatment, patients had a median CD4 count of
115 (IQR 62–213) cells/μl and HIV-1 RNA of 4.8
(IQR 4.2–5.3) log10 copies/ml. Most of the patients
(77%) received tenofovir (TDF) as part of their sec-
ond-line ART regimen. All second-line regimens
were based on LPV/r. Two patients were prescribed
ritonavir-boosted raltegravir (RAL/r) and etravirine
(ETV) combined with LPV/r as part of their second-
line regimen. Median follow-up duration on second-
line ART was 24 (IQR 12–34) months. The maximum
duration of second-line treatment of the patients who
were still under care without virological failure was 7
years.
Virological failure on second-line ART
Of 824 patients, 52 (6%) patients received viral load
testing after initiation of second-line treatment dur-
ing the study period and 19 (37% of those tested)
were diagnosed with virological failure according to
WHO criteria. None of these 19 patients switched to
third-line ART during the study period. The inci-
dence rate of virological failure after starting sec-
ond-line ART was 1 patient per 100 person years
follow-up (PYFU) (95% CI: 0.7–1.7). The cumulative
probability of virological failure at year 7 was 6%
(95% CI: 3–9%) (Figure 1).
Program outcomes
Among 824 patients on second-line ART, 88 patients
(11%) died, 35 (4%) patients were lost to follow-up,
21 (2%) were transferred out to other health facilities
and 680 (83%) were retained under care at the end of
the study period. Of 88 deaths, 48 (55%) patients died
within 1 year of starting second-line ART. Of 35
patients lost to follow-up, 17 (48%) were also lost to
follow-up within 1 year. Of 19 patients who experi-
enced virological failure, 12 patients were still under
care, 1 patient was transferred out, 5 patients died
and 1 patient was lost to follow-up at the end of the
study period. The incidence rate of death and lost to
follow-up combined was 7 patients per 100 PYFU
(95% CI: 6–8) and the cumulative probability of
death and lost to follow-up at year 7 was 26% (95%
CI: 20–33) (Figure 2).
Overall, 136 (17%) patients’ outcomes were
unfavorable (failure, death, lost to follow-up) at
the end of the study period. The probability of an
unfavorable outcome at year 1 was 8% (95% C.I:
7–11), at year 2 it was 15% (95% CI: 13–18) and at
year 7 it was 30% (95% CI: 25–37%) (Figure 3); the
incidence rate of unfavorable outcomes across the
study period was 7.9 per 100 PYFU (95% CI: 6.7–
9.3). This rate was different among sub-groups
(Table 2).
Factors associated with unfavorable outcomes
Factors associated with unfavorable outcomes are
shown in Table 3. In unadjusted analysis, patients
with a history of injecting drug use, a history of
being lost to follow-up, having a higher baseline
viral load and who received ddI+ABC as the NRTI
(nucleoside reverse-transcriptase inhibitors) drug
class in the lopinavir-based regimen had a signifi-
cantly higher risk of unfavorable outcomes. Patients
with higher CD4 cell counts at baseline, having
taken first-line ART at a private clinic, receiving
ART at decentralized sites, having a longer duration
on second-line ART and taking ZDV+3TC had a
significantly lower risk of unfavorable outcomes. In
the adjusted analysis, receiving ddI+ABC, duration
on second-line ART and taking ART at decentra-
lized sites still had statistically significant
associations.
Discussion
This study is the first to report on the outcomes of a
second-line ART cohort of patients being managed in
a public health setting in Myanmar. Treatment failure
was suspected based on clinical and immunological
criteria and only these patients received viral load
testing. The WHO recommends systematic viral
load testing for all patients (at sixth month after
treatment and yearly thereafter to monitor virological
response) [11]. However, there is no systematic viral
load testing available in this setting and hence the
number of patients who received viral load testing
4 N. T. T. KYAW ET AL.
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Table 1. Socio-demographic and clinical characteristics of patients who started second-line ART at the IHC Program, Myanmar
between 2008 and 2015, stratified by treatment outcomes.
Socio-demographic characteristics
Failure Death/Lost to follow-up Favorable outcome Total
n (%) n (%) n (%) n (%)
All patients 824 (100)
Gender Male 10 (53) 85 (73) 437 (64) 532 (65)
Female 9 (47) 32 (27) 251 (36) 292 (35)
Age group Adolescent (10–19 years) 3 (16) 4 (3) 35 (5) 42 (5)
Adult (> 19 years) 16 (84) 113 (97) 653 (95) 782 (95)
Marital status Single 7 (37) 35 (30) 181 (26) 223 (27)
Married 8 (42) 56 (48) 372 (54) 436 (53)
Widowed 4 (21) 16 (14) 103 (15) 123 (15)
Divorced/separate 0 (0) 6 (5) 23 (3) 29 (4)
Missing 0 (0) 4 (3) 9 (1) 13 (2)
Employment status Employed 11 (58) 83 (71) 484 (70) 578 (70)
Unemployed 8 (42) 33 (28) 198 (29) 239 (29)
Missing 0 (0) 1 (1) 6 (1) 7 (1)
Literacy Literate 13 (68) 111 (95) 615 (89) 739 (90)
Illiterate 6 (32) 5 (4) 68 (10) 79 (10)
Missing 0 (0) 1 (1) 5 (1) 6 (1)
HIV transmission risk Heterosexual 13 (68) 92 (79) 573 (83) 678 (82)
Men sex with men 0 (0) 4 (3) 16 (2) 20 (2)
Sex work 0 (0) 0 (0) 1 (0) 1 (0)
Injecting drug use 1 (5) 8 (7) 14 (2) 23 (3)
Blood transfusion 2 (11) 6 (5) 24 (3) 32 (4)
Mother to child 3 (16) 2 (2) 32 (5) 37 (4)
Unknown 0 (0) 5 (15) 28 (85) 33 (4)
Caretaker Yes 18 (95) 84 (72) 528 (77) 630 (76)
No 1 (5) 33 (28) 160 (23) 194 (24)
Region of ART clinic Mandalay 16 (84) 89 (76) 444 (65) 549 (67)
Sagaing 0 (0) 6 (5) 64 (9) 70 (9)
Magway 1 (5) 4 (3) 73 (11) 78 (9)
Shan 0 (0) 15 (13) 55 (8) 70 (9)
Yangon 2 (11) 3 (3) 52 (8) 57 (7)
On ART before enrolled to IHC Private 19 (100) 78 (67) 432 (63) 529 (64)
Public 0 (0) 29 (25) 198 (29) 227 (28)
Unknown place 0 (0) 9 (8) 44 (6) 53 (6)
Naïve 0 (0) 1 (1) 14 (2) 15 (2)
Baseline characteristics
Duration on first-line ART < 1 year 1 (5) 16 (14) 74 (11) 91 (11)
1–2 years 6 (32) 45 (38) 211 (31) 262 (32)
> 2 years 12 (63) 56 (48) 403 (59) 471 (57)
First-line ART modification (times) No change 6 (32) 55 (47) 377 (55) 438 (53)
Three times 13 (68) 60 (51) 287 (42) 360 (44)
More than three times 0 (0) 2 (2) 24 (3) 26 (3)
Lost to follow-up (number of times) No lost to follow-up 12 (63) 81 (69) 564 (82) 657 (80)
1 time 4 (21) 29 (25) 101 (15) 134 (16)
> 1 time 3 (16) 7 (6) 23 (3) 33 (4)
Delayed switching to second-line ART Within 4 months 15 (79) 92 (79) 560 (81) 667 (81)
Delayed 1 (5) 14 (12) 79 (12) 94 (11)
Missing failure date 3 (16) 11 (9) 49 (7) 63 (8)
C.D.4 count (cells/µl) More than 350 2 (11) 4 (3) 71 (10) 77 (9)
Between 100 and 350 4 (21) 39 (33) 336 (49) 379 (46)
Less than 100 13 (68) 74 (63) 280 (41) 367 (45)
Missing 0 (0) 0 (0) 1 (0) 1 (0)
WHO staging Stage I/II 4 (21) 28 (24) 175 (25) 207 (25)
Stage III/IV 15 (79) 89 (76) 513 (75) 617 (75)
Viral load (copies/ml) < 10,000 0 (0) 9 (8) 65 (9) 74 (9)
> 10,000 12 (63) 67 (57) 407 (59) 486 (59)
Missing 7 (37) 41 (35) 216 (31) 264 (32)
Hepatitis B Negative 19 (100) 90 (77) 587 (85) 696 (84)
Positive 0 (0) 18 (15) 68 (10) 86 (10)
Missing 0 (0) 9 (8) 33 (5) 42 (5)
Hepatitis C Negative 19 (100) 102 (87) 627 (91) 748 (91)
Positive 0 (0) 7 (6) 28 (4) 35 (4)
Missing 0 (0) 8 (7) 33 (5) 41 (5)
Follow-up characteristics
Current ART site ART Center 18 (95) 106 (91) 459 (67) 583 (71)
Decentralized site 1 (5) 11 (9) 229 (33) 241 (29)
Duration on second-line ART < 1 year 0 (0) 65 (56) 153 (22) 218 (26)
1–2 years 3 (16) 27 (23) 172 (25) 202 (25)
> 2 years 16 (84) 25 (21) 363 (53) 404 (49)
NRTI class TDF-based 17 (89) 88 (75) 528 (77) 633 (77)
d.d.I+ABC 1 (5) 12 (10) 20 (3) 33 (4)
ABC+3T.C 1 (5) 6 (5) 51 (7) 58 (7)
AZT+3T.C 0 (0) 8 (7) 84 (12) 92 (11)
d4T+3T.C 0 (0) 2 (2) 3 (0) 5 (1)
ETV 0 (0) 1 (1) 1 (0) 2 (0)
Missing 0 (0) 0 (0) 1 (0) 1 (0)
Notes: ART = antiretroviral treatment; WHO = World Health Organization; IHC = Integrated HIV Care Program; NRTI = nucleoside reverse-transcriptase
inhibitors; NNRTI = non-nucleoside reverse-transcriptase inhibitors; TDF = tenofovir; d.d.I = didanosine; ABC = abacavir; AZT = zidovudine;
3TC = lamivudine; d4T = stavudine; ETV = etravirine.
n (%) = number (percentage). Percentages are column percentages.
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was lower than the numbers that should have been
tested.
The failure rate and overall outcomes of this
patient cohort are better than in other studies from
similar resource-limited settings [2,5,7,8,13]. A multi-
centric study with follow-up duration of three years
showed that the probability of survival at one year
was 0.86 and at two years it was 0.77 [8]. A study
from Vietnam reported that 9.5% of patients on sec-
ond-line ART had failure during 6-year follow-up
[14]. There were substantial early mortality and loss
to follow-up in this study but the outcomes are better
in the later years among the survivors. This result is
consistent with a study from India which is similar to
our study setting where routine viral load monitoring
was not available. This India study showed that the
death rate was higher in the first year (13.7 patients
per 100 PYFU in first year vs 3.9 patients per 100
PYFU between 1 and 5 years after second-line treat-
ment) mainly due to the longer duration of patients
failing on first-line ART as a result of delays in failure
diagnosis using clinical and immunological criteria
and having poor clinical condition at the start of
second-line ART [2].
Adolescents only accounted for 5% of this second-
line ART cohort although the evidence suggests that
the adolescent age group is more likely to fail on first-
line ART due to complex psychosocial, behavioral
and clinical reasons [14–17]. More research is needed
in Myanmar to explore whether the HIV-infected
adolescents lack adequate access to care or if the
care is not tailored to their age group.
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Figure 1. Number of patients and cumulative probability of virological failure in second-line ART cohort at IHC, Myanmar
between 2008 and 2015.
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Myanmar has a concentrated HIV epidemic. The
HIV burden was very high in key populations with
HIV prevalence rates ranging from 6% to 23% while
HIV prevalence in the general population was 0.5% in
2015 [18]. In addition, key populations are more
likely to experience treatment failure and unfavorable
outcomes [19,20]. However, our result showed that
only 5% of the second-line ART cohort belonged to
key populations (commercial sex workers, men who
have sex with men and injection drug users). This
might be because a large proportion of key popula-
tions are not accessing HIV testing services in the
first place, not starting on HIV treatment, not having
access to second-line treatment or not disclosing their
real HIV risk to their care provider [21,22]. All these
issues need to be further explored in order to better
understand and perhaps modify the services provided
to these key populations.
One in five patients in this cohort experienced
delayed switching to second-line treatment. This
delay in treatment is not uncommon in many
resource-limited countries [23,24]. Treatment provi-
ders are often reluctant to switch early due to limited
diagnostic tools such as HIV viral load testing and
drug resistance testing, the difficulties in ensuring
that patients are adherent to medication and the
availability and costs of the second-line drugs [25].
Although more than half of this cohort was on
ART for more than 2 years, only 6% of patients
were tested for HIV viral load after 6 months of
second-line therapy. This can explain the lower
rates of virological failure and may indicate the
under-diagnosis of second-line treatment failure.
In addition, the evidence suggests that most of the
second-line treatment failure cases are not actually
resistant to second-line therapy in the initial years
of treatment and they have high viral loads due to
problems with drug adherence [26].
Among the 19 patients whomet the virological failure
criteria, none of them were switched to a third-line regi-
men. As there is no information on their patterns of HIV
drug resistance, it is difficult to know whether their
therapy was not modified because it was deemed clini-
cally unnecessary to switch or because the third-line ART
regimen was not available in the program. This under-
scores the need for HIV drug resistance testing in
Myanmar for those patients diagnosed with second-line
ART failure and the need for third-line ART for those
with confirmed resistance to second-line ART to prevent
further transmission of resistant HIV.
Risk factors for unfavorable outcomes in our own
study and in other studies have consistently included
high viral load and low CD4 counts at baseline, hav-
ing a history of being lost to follow-up and experien-
cing delayed switching to second-line ART after first-
line failure [2,7,8,13,25]. Although there were small
numbers of patients who were injection drug users in
our study, they have a higher risk of developing
unfavorable outcomes similar to what has been
shown elsewhere [21].
In this cohort, about one third of patients receiv-
ing second-line ART were at a decentralized site and
they had better outcomes than people in the ART
Center. The probable reason is that these patients had
good ART outcomes in general because only those
who are clinically stable are referred to a decentra-
lized site. This highlights the success of the decentra-
lization strategy by the national program to bring the
treatment including second-line treatment nearer to
the patients’ residence for easy access.
We also noted that patients who had a history of
receiving treatment at private clinics before coming
0
.1
.2
.3
.4
.5
P
ro
po
rt
io
n 
of
 p
at
ie
nt
 w
ith
 u
nf
av
or
ab
le
 o
ut
co
m
es
0 2 4 6 8
Years on second line ART
823 396(102) 82(31) 17(2) 0(0)
At risk (Event)
Kaplan-Meier estimate
Figure 3. Number of patients and cumulative probability of unfavorable outcomes (failure, death and lost to follow-up
combined) in second-line ART cohort at IHC, Myanmar between 2008 and 2015.
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to IHC had a better outcome. There is no study
comparing outcomes between the public and private
sectors. However, we assume that the patients who
seek care from the private sector are more likely to be
well-off economically and hence might have main-
tained better adherence to the treatment.
Strengths
This study had a large sample size with a long dura-
tion of follow-up of patients on second-line ART in
comparison with other studies. The study was based
on routinely collected public health program data
which can reflect the reality of second-line ART
management in a resource-limited setting. We used
standard virological failure and other programmatic
outcomes definitions in accordance with WHO
guidelines, enabling comparisons with the findings
from other studies. We had robust and reliable data
with dates of outcomes for each patient, thus enabling
time-to-event analysis. We also reported this study
according to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
guidelines [27].
Table 2. Incidence rates of unfavorable outcomes among patients on second-line ART in the IHC
Program, Myanmar between 2008 and 2015.
Baseline characteristics Rate (95% CI) per 100 PYFU
Total 7.9 (6.7–9.3)
Gender Male 6.9 (5–9.3)
Female 8.4 (6.9–10.3)
Age group Adult 7.8 (6.5–9.3)
Adolescent 10.4 (5–21.8)
Transmission risk Heterosexual 7.2 (5.9–8.7)
Men sex with men 8 (3–21.2)
Injecting drug use 24.5 (12.8–47.2)
Blood transfusion 12.3 (6.2–24.6)
Mother to child 7.9 (3.3–19)
Unknown 10 (4.1–23.9)
Caretaker Yes 8.3 (6.9–10.1)
No 6.8 (4.8–9.6)
ART before enrolled Private 5.2 (3.6–7.6)
Public 6.2 (3.2–11.9)
Unknown 2.5 (0.3–17.6)
Naïve 9.8 (8–12)
Duration on first-line ART < 1 year 6.8 (4.1–11.1)
1–2 years 9.5 (7.2–12.5)
> 2 years 7.2 (5.7–9.2)
First-line ART modification (times) No Rx changed 7 (5.4–9)
1–3 times 9 (7.2–11.3)
> 3 times 4.4 (1.1–17.4)
Lost to follow-up (number of times) No lost to follow-up 6.7 (5.4–8.2)
1 time 12.7 (9–17.9)
> 1 times 13.7 (7.4–25.5)
Delayed switching to second-line ART Switch within 4 months 7.4 (6.1–8.9)
Delayed 10.8 (7.4–15.6)
C4 count (cells/µl) More than 350 4.7 (2.1–10.5)
Between 100 and 350 5.3 (3.9–7.2)
Less than 100 11.1 (9–13.7)
WHO staging Stage I/II 7.8 (5.5–11.1)
Stage III/IV 7.9 (6.5–9.6)
Viral load (copies/ml) < 10,000 5.6 (2.9–10.8)
> 10,000 7.7 (6.2–9.6)
Missing 8.9 (6.7–11.8)
Hepatitis B No 7.6 (6.3–9.1)
Yes 8.6 (5.4–13.8)
Missing 12.2 (6.3–23.4)
Hepatitis C No 7.7 (6.4–9.2)
Yes 9.2 (4.4–19.4)
Missing 10.9 (5.4–21.8)
Current ART site ART sites 12 (10.1–14.4)
D.C sites 1.7 (1–3.1)
Duaration on second-line ART < 1 year 58.6 (45.9–74.9)
1–2 years 9.8 (6.8–14)
> 2 years 3.2 (2.3–4.3)
NRTI and NNRTI class TDF-based 7.5 (6.2–9.1)
d.d.I+ABC 8.6 (5–14.8)
ABC+3TC 8.4 (4–17.6)
AZT+3TC 11.1 (5.6–22.3)
D4T+3TC 18.5 (4.6–74)
ETV 59 (8.3–418.9)
Notes: PYFU = person years follow-up; ART = antiretroviral treatment; WHO = World Health Organization;
IHC = Integrated HIV Care Program; NRTI = nucleoside reverse-transcriptase inhibitors; NNRTI = non-nucleoside
reverse-transcriptase inhibitors; TDF = tenofovir; ddI = didanosine; ABC = abacavir; AZT = zidovudine;
3TC = lamivudine; d4T = stavudine; ETV = etravirine.
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Limitations
There is risk of selection bias as we excluded patients
who were on a LPV/r-based regimen with no docu-
mentation of the reason for switching from first-line
ART to a LPV/r-based regimen and who were already
on a LPV/r-based regimen when they registered at
IHC. In addition, there is no information on clinical
and immunological failure diagnosed by the clinician
in patients on second-line ART who did not receive
viral load testing. Hence, there may be an under-
estimation of the treatment failure rate in this study.
A few patients had had HIV drug resistance testing
done with out-of-pocket expenditure but the results
were not documented in this database. We do not
have data on cause of death and cannot therefore
determine if the death was HIV-related or not.
Conclusions
Long-term outcomes of patients on second-line ART
were relatively good in this cohort. Most of the deaths
and loss to follow-up occurred in the first year of
treatment. A low percentage was found to have vir-
ological failure because only a very small percentage
of patients was tested for viral load. Thus, routine
viral load monitoring is recommended for the cohort
of second-line ART patients. Finally, the National
HIV/AIDS Program should consider making avail-
able third-line ART drugs for such patients after a
careful cost–benefit analysis.
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Paper context
While second-line antiretroviral treatment (ART) has been
available since 2008 in Myanmar, there has not yet been an
assessment of patient outcomes. The rate of unfavorable
outcomes (failure, death, lost-to-follow-up) among 824
patients was relatively low at 7.9 per 100 person-years.
However, only 52 received HIV viral load tests and 19
who failed treatment were not changed to third-line ART.
The Myanmar National HIV/AIDS Program should con-
sider making routine viral load monitoring and third-line
ART drugs available.
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